Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs with Risk for Attention-Deficit/Hyperactivity Disorder in Offspring
JAMA Netw Open 2:e186606, Christensen, J.,et al, 2019
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Monoamine Oxidase Inhibitors
Adams & Victors Principles of Neurology Chp 43, pg 1210, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Tricyclic Antidepressants
Adams & Victors Principles of Neurology Chp 43, pg 1211, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins and Chemical Agents, Mescaline, LSD, and Psilocybin
Adams & Victors Principles of Neurology Chp 43. pg 1215, Ropper, A.H.,et al, 2014
ADHD Drugs and Cardiovascular Risk
NEJM 354:1445-1448, Nissen,S.E., 2006
Dementia with Lewy Bodies
Lancet 362:1689-1690, Wilcock,G.K., 2003
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Treatment of Attention-Deficit-Hyperactivity Disorder
NEJM 340:780-788, Elia,J.,et al, 1999
A 55-Year-Old Man with Attention-Deficit/Hyperactivity Disorder
JAMA 280:1086-1092, Biederman,J., 1998
Medication for Children with Attentional Disorders
Pediatrics 98:301-304, Perrin,J.,et al, 1996
Serotonin Syndrome
Neurol 45:219-223, Bodner,R.A.,et al, 1995
Neurotoxicity in Liver Transplant Recipients with Cyclosporine Immunosuppression
Neurol 45:1962-1964, Wijdicks,E.F.M.,et al, 1995
Aspartame, Behavior, and Cognitive Function in Children with Attention Deficit Disorder
Pediatrics 93:70-75, 127-1281994., Shaywitz,B.A.,et al, 1994
Effects of Diets High in Sucrose or Aspartame on the Behavior and Cognitive Performance of Children
NEJM 330:301-307, 3551994., Wolraich,M.L.,et al, 1994
Adderall and Other Drugs for Attention-Deficit/Hyperactivity Disorder
The Medical Letter, 36:109-1101994., , 1994
Cognitive Functioning after Common Whiplash, A Controlled Follow-up Study
Arch Neurol 50:87-91, Radanov,B.P.,et al, 1993
Effects of Antiepileptic Drugs on Reaction Time, Attention, and Impulsivity in Children
pediatrics 91:101-105, Mitchell,W.G.,et al, 1993
Ranitidine Pharmacokinetics and Adverse Central Nervous System Reactions
Arch Int Med 152:2325-2329, Slugg,P.H.,et al, 1992
Side Effects of Methylphenidate in Children with Attention Deficit Hyperactivity Disorder
Pediatrics 86:184-192, Barkley,R.A.,et al, 1990
Depression of Growth in Hyperactive Children on Stimulant Drugs
NEJM 287:217, 1972; 287:249972., Safer,D.,et al, 1972
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Medical Use of Cannabis in 2019
JAMA 322:974-975, Hill, K.P., 2019
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
NEJM 376:2011-2020, Devinsky, O.,et al, 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Synthetic Cannabinoid-Related Illnesses and Deaths
NEJM 373:103-107, Trecki, J.,et al, 2015
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Early Child Development and Exposure to Antiepileptic Drugs Prenatally and Through Breastfeeding
JAMA Neurol 70:1367-1374, Veiby, G.,et al, 2013
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Child Development Following In Utero Exposure: Levetiracetam vs Sodium Valproate
Neurol 76:383-389, Shallcross,R.,et al, 2011
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
Neurol 76:1697-1704, Vermersch,P.,et al, 2011
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006